April 17th 2024
The concept of sludge provides an invaluable lens for clinical research professionals in identifying and mitigating unnecessary friction and bottlenecks.
Bristol Myers Squibb Enhances Early Stage Oncology Clinical Pipeline With Mirati Acquisition
January 24th 2024Mirati’s oncology portfolio includes promising early phase clinical assets such as a potential first-in-class MTA-cooperative PRMT5 inhibitor and a leading KRAS and KRAS enabling program with a pair of candidates in Phase I development.
Micah Lieberman of ClinEco Speaks on the Organization’s Clinical Trials Ecosystem
January 18th 2024In an interview with ACT editor, Andy Studna, Lieberman, Executive Director, Conferences (CHI) & Co-Founder, VP, Community and Business Development (ClinEco) discusses what ClinEco is and how the need to create it came about.
BMS Reaches Deal to Codevelop Antibody-Drug Conjugate That Has Shown Promise in Early Trials
December 12th 2023BL-B01D1 is a potentially first-in-class EGFRxHER3 bispecific antibody-drug conjugate currently being evaluated in the global, multi-center Phase I BL-B01D1-LUNG101 trial in patients with metastatic or unresectable non-small cell lung cancer.